Ajanta Pharma informs about updates
Ajanta Pharma has informed that the US FDA has concluded an inspection at its manufacturing facility at Paithan, in Maharashtra. The Inspection was conducted from April 13th, 2026, to April 21, 2026, and closed with the issuance of Form-483 with 5 observations. The Company will respond to the US FDA within the stipulated timeline.
The above information is a part of company’s filings submitted to BSE.
